2015
DOI: 10.4274/tod.41275
|View full text |Cite
|
Sign up to set email alerts
|

Assessment of Bone Mineral Density in Osteoporosis

Abstract: Osteoporoz; düşük kemik kütlesi, kemik mikromimarisinde bozulma ve kırık riskinde artış ile karakterize, yaygın ve sessiz bir hastalıktır. Bununla birlikte, kırık oluşmadan önce önlenebilir, tanı konabilir ve tedavi edilebilir. Kemik mineral yoğunluğu değerlendirmesi, osteoporoz tanısı koymada önemli bir rol oynar. Kemik mineral yoğunluğu ölçümünde dual X-ışını absorbsiyometri, kantitatif bilgisayarlı tomografi, kantitatif ultrason, dijital X-ışını radyogrametri ve radyografik absorbsiyometri gibi çeşitli görü… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4

Citation Types

0
6
0
1

Year Published

2016
2016
2021
2021

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(9 citation statements)
references
References 7 publications
0
6
0
1
Order By: Relevance
“…DXA allows accurate diagnosis of osteoporosis, helps to determine the estimate fracture risk and monitoring of patients undergoing treatment (1)(2)(3)(4)(5). The primary target of DXA is to quantify BMD accurately and reproducibly and to compare that measurement with a reference population of asymptomatic individuals.…”
Section: Introductionmentioning
confidence: 99%
See 4 more Smart Citations
“…DXA allows accurate diagnosis of osteoporosis, helps to determine the estimate fracture risk and monitoring of patients undergoing treatment (1)(2)(3)(4)(5). The primary target of DXA is to quantify BMD accurately and reproducibly and to compare that measurement with a reference population of asymptomatic individuals.…”
Section: Introductionmentioning
confidence: 99%
“…Low measurement values on DXA predict the risk of fractures of the spine and hip, analogous to the relationship between high serum cholesterol and the risk of heart disease, or between high blood pressure and the risk of stroke. DXA is also useful in evaluating the effectiveness of FDA-approved therapies for osteoporosis, such as alendronate, risedronate, and raloxifene (1,2,(4)(5)(6).…”
Section: Introductionmentioning
confidence: 99%
See 3 more Smart Citations